The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of twice-daily (BID) cytarabine (A) and fludarabine (F) and gentuzumab ozogamycin (GO) in patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
H. Ghanem
No relevant relationships to disclose
H. Kantarjian
No relevant relationships to disclose
G. Garcia-Manero
No relevant relationships to disclose
F. Ravandi
No relevant relationships to disclose
S. Faderl
No relevant relationships to disclose
J. E. Cortes
No relevant relationships to disclose
A. Reyes
No relevant relationships to disclose
S. M. O'Brien
No relevant relationships to disclose
G. Borthakur
No relevant relationships to disclose
T. M. Kadia
No relevant relationships to disclose
J. A. Burger
No relevant relationships to disclose
M. Konopleva
No relevant relationships to disclose
E. Jabbour
No relevant relationships to disclose